Immusoft, Takeda ink metabolic disorder cell therapy deal

By The Science Advisory Board staff writers

October 13, 2021 -- Immusoft has signed a research and licensing deal with Takeda Pharmaceutical to develop cell therapies for rare inherited metabolic disorders that have manifestations in the central nervous system.

The collaboration will focus on delivering protein therapeutics across the blood-brain barrier. Under the terms of the agreement, Immusoft will receive an undisclosed upfront payment and research funding support. The company is also eligible to receive future option fees and milestone payments with a total potential value of more than $900 million.

Immusoft is eligible for tiered royalties on future products resulting from the partnership, and Takeda would be responsible for further preclinical and clinical development and commercialization.


Copyright © 2021 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.